Carr Financial Group Corp Makes New Investment in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Carr Financial Group Corp purchased a new position in Coherus BioSciences, Inc. (NASDAQ:CHRS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 35,195 shares of the biotechnology company’s stock, valued at approximately $117,000.

A number of other hedge funds also recently modified their holdings of the stock. Hsbc Holdings PLC grew its stake in Coherus BioSciences by 90.9% in the 3rd quarter. Hsbc Holdings PLC now owns 83,329 shares of the biotechnology company’s stock valued at $313,000 after buying an additional 39,669 shares in the last quarter. Swiss National Bank grew its stake in Coherus BioSciences by 16.6% in the 3rd quarter. Swiss National Bank now owns 209,100 shares of the biotechnology company’s stock valued at $782,000 after buying an additional 29,800 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Coherus BioSciences in the 3rd quarter valued at approximately $203,000. Brandywine Global Investment Management LLC grew its stake in Coherus BioSciences by 64.7% in the 3rd quarter. Brandywine Global Investment Management LLC now owns 666,245 shares of the biotechnology company’s stock valued at $2,492,000 after buying an additional 261,800 shares in the last quarter. Finally, Barclays PLC grew its stake in Coherus BioSciences by 3,105.3% in the 3rd quarter. Barclays PLC now owns 2,375,557 shares of the biotechnology company’s stock valued at $8,884,000 after buying an additional 2,301,444 shares in the last quarter. Institutional investors own 72.82% of the company’s stock.

Wall Street Analyst Weigh In

CHRS has been the subject of a number of recent analyst reports. Robert W. Baird reduced their price target on shares of Coherus BioSciences from $11.00 to $9.00 and set an “outperform” rating for the company in a research report on Tuesday, January 23rd. Truist Financial lowered their price objective on shares of Coherus BioSciences from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, January 23rd. Finally, HC Wainwright lowered their price objective on shares of Coherus BioSciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, March 20th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $9.29.

Coherus BioSciences Trading Down 0.8 %

CHRS traded down $0.02 during midday trading on Wednesday, reaching $2.45. The company’s stock had a trading volume of 1,630,025 shares, compared to its average volume of 4,056,609. The firm has a market capitalization of $276.14 million, a price-to-earnings ratio of -0.96 and a beta of 0.54. Coherus BioSciences, Inc. has a 1 year low of $1.43 and a 1 year high of $8.65. The stock’s 50-day moving average is $2.40 and its 200-day moving average is $2.61.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.39). The business had revenue of $91.52 million for the quarter, compared to analyst estimates of $105.30 million. As a group, equities research analysts forecast that Coherus BioSciences, Inc. will post -0.56 earnings per share for the current fiscal year.

Coherus BioSciences Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.